Rhea-AI Summary
Cellular Biomedicine Group (NASDAQ: CBMG) presented its poster titled "Selecting Clinical Lead of TCRs Targeting Alpha-Fetoprotein-Positive Liver Cancer on Balance of Risk and Benefit" at the 2020 AACR annual meeting held virtually from June 22-24. The poster discusses C-TCR055, CBMG's proprietary T cell receptor targeting alpha-fetoprotein (AFP) in hepatocellular carcinoma (HCC). Preclinical studies indicate C-TCR055 possesses a strong safety profile and anti-tumor activity. A Phase I clinical trial is currently ongoing at Fudan University for patients with unresectable HCC (NCT03971747).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.06%
Tags